Luke Halpern

2 days ago | pharmacytimes.com | Luke Halpern

Pharmacies have vast and specialized product inventories that require special attention and comprehensive internal controls to increase efficiency and safeguard medicines. Proper handling and organization of pharmacy inventory is a critical component of safe medication packaging, which helps prevent medication error, a scourge on patients that results in countless injuries and billions in complication costs.

2 days ago | pharmacytimes.com | Luke Halpern

Rates of pneumococcal vaccination among eligible adults continue to lag desired targets for optimal protection across communities. The CDC, following a 2022 National Health Interview Survey, reported that pneumococcal vaccine coverage among adults at increased risk for invasive pneumococcal disease (IPD) was only 23.0% in 2022, while it was 64.0% for those aged 65 years or older.

3 days ago | pharmacytimes.com | Luke Halpern

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) was safe and effective at inducing and maintaining clinical remission for up to 24 months in patients with idiopathic inflammatory myositis (IIM), according to the results of a trial published by investigators in the European Journal of Internal Medicine.1 Nature of IIM Necessitates Novel Approaches IIM is one of many heterogeneous diseases that share a chronic inflammation of skeletal muscle, with frequent...

3 days ago | pharmacytimes.com | Luke Halpern |Saad Usmani

CommentaryVideoJune 4, 2025Author(s):,Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

4 days ago | pharmacytimes.com | Luke Halpern

Coverage of this story is ongoing. The FDA has approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), according to a news release from the agency.1Efficacy of darolutamide in patients with mCSPC was evaluated in the phase 3 ARANOTE study (NCT04736199), in which 669 patients were randomly assigned to receive darolutamide 600 mg twice daily or placebo.